INBP — Integrated Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00- $8.79m
- $6.33m
- $50.32m
- 100
- 99
- 52
- 97
Annual cashflow statement for Integrated Biopharma, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 4.11 | 8.01 | 3.84 | -0.034 | 0.112 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.377 | -0.869 | 0.882 | 1.15 | 1.13 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.11 | -3.05 | 0.565 | -0.302 | -0.744 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | 1.34 | 3.05 | 4.09 | 1.23 | 0.943 |
| Capital Expenditures | -0.214 | -0.295 | -0.486 | -0.116 | -0.553 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.104 | 0.096 | 0.021 | 0.005 | 0 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Cash from Investing Activities | -0.11 | -0.199 | -0.465 | -0.111 | -0.553 |
| Financing Cash Flow Items | 0 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -1.3 | -3.04 | -3.5 | -0.136 | -0.029 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.073 | -0.192 | 0.121 | 0.985 | 0.361 |